Recent Price Action Shows Strength MRNA has shown significant bullish momentum since mid-May 2025, rising from around $24 to current levels above $34, representing a 40%+ gain. The stock has formed a series of higher lows and higher highs, establishing a clear uptrend.
Key Bullish Factors:
Positive FDA Developments
Full FDA approval for COVID-19 vaccine Spikevax for children 6 months through 11 years (July 10)
European Medicines Agency's positive opinion for updated COVID-19 vaccine formulation (July 25)
Technical Breakout
The stock broke above its resistance level around $30 in early July
Volume has increased on up days, particularly on July 8-9 (19.3M shares) and July 22-23 (12.5M shares), indicating strong buying interest
Cancer Vaccine Progress
Recent news (July 23) about researchers moving closer to a universal cancer vaccine, which aligns with Moderna's mRNA technology platform
Relative Value Opportunity
Market cap has decreased significantly from $44.4B in Q2 2024 to $10.9B in Q1 2025
Current price represents a potential value opportunity if the company can return to profitability
Price Structure Analysis:
08 Apr
15 Apr
22 Apr
29 Apr
06 May
13 May
20 May
27 May
03 Jun
10 Jun
17 Jun
24 Jun
01 Jul
08 Jul
15 Jul
22 Jul
25
30
35
MRNA Close Price
Support Levels
FDA Approval
EMA Positive Opinion
Entry Strategy:
Current price ($34.15) offers a potential entry point with strong support at the $32-33 level
Volume profile suggests accumulation phase may be underway
Risk can be managed with a stop loss below $32
Potential Catalysts:
Additional vaccine approvals or expanded indications
Progress in cancer vaccine development
Return to profitability in upcoming earnings reports
Potential for inclusion in seasonal vaccination programs
Risk Factors to Monitor:
Bank of America maintains a "sell" rating with a $25 price target
Negative PE ratio indicates the company is not currently profitable
News about Japan plant cancellation suggests demand challenges
Political uncertainty around vaccine policies
Key Bullish Factors:
Positive FDA Developments
Full FDA approval for COVID-19 vaccine Spikevax for children 6 months through 11 years (July 10)
European Medicines Agency's positive opinion for updated COVID-19 vaccine formulation (July 25)
Technical Breakout
The stock broke above its resistance level around $30 in early July
Volume has increased on up days, particularly on July 8-9 (19.3M shares) and July 22-23 (12.5M shares), indicating strong buying interest
Cancer Vaccine Progress
Recent news (July 23) about researchers moving closer to a universal cancer vaccine, which aligns with Moderna's mRNA technology platform
Relative Value Opportunity
Market cap has decreased significantly from $44.4B in Q2 2024 to $10.9B in Q1 2025
Current price represents a potential value opportunity if the company can return to profitability
Price Structure Analysis:
08 Apr
15 Apr
22 Apr
29 Apr
06 May
13 May
20 May
27 May
03 Jun
10 Jun
17 Jun
24 Jun
01 Jul
08 Jul
15 Jul
22 Jul
25
30
35
MRNA Close Price
Support Levels
FDA Approval
EMA Positive Opinion
Entry Strategy:
Current price ($34.15) offers a potential entry point with strong support at the $32-33 level
Volume profile suggests accumulation phase may be underway
Risk can be managed with a stop loss below $32
Potential Catalysts:
Additional vaccine approvals or expanded indications
Progress in cancer vaccine development
Return to profitability in upcoming earnings reports
Potential for inclusion in seasonal vaccination programs
Risk Factors to Monitor:
Bank of America maintains a "sell" rating with a $25 price target
Negative PE ratio indicates the company is not currently profitable
News about Japan plant cancellation suggests demand challenges
Political uncertainty around vaccine policies
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.